Diaceutics (DXRX) AI Stock Analysis

• Market Cap: £108.29M
• Dividend Yield: N/A
• Average Volume (3M): 80.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: 31.83%
• EPS Growth: 46.59%
• Country: UK
• Employees: 184
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.03
• Shares Outstanding: 84,905,950
• 10 Day Avg. Volume: 66,090
• 30 Day Avg. Volume: 80,146
• PEG Ratio: 25.77
• Price to Book (P/B): 2.66
• Price to Sales (P/S): 3.30
• P/FCF Ratio: -26.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £225.00
• Price Target Upside: 39.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 1.77
• Revenue Forecast (FY): £3.98B

• Rating: 57 Neutral
• Price Target: 142.00p ▼(-12.07% Downside)

Diaceutics' strong revenue growth and positive corporate events are overshadowed by challenges in profitability, cash flow, and bearish technical indicators. The stock's valuation is also concerning due to negative earnings.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and demand for Diaceutics' solutions, supporting long-term business expansion.

Balance Sheet Health

A strong balance sheet with minimal debt enhances financial stability and provides flexibility for strategic investments and growth.

Business Model

A diversified revenue model with long-term contracts and partnerships ensures steady income and reduces dependency on single revenue streams.

Negative Factors

Profitability Challenges

Ongoing profitability issues may hinder reinvestment capabilities and affect long-term financial health if not addressed.

Cash Flow Decline

Negative cash flow impacts liquidity and may constrain operational flexibility, necessitating improved cash management strategies.

Equity Decline

A decline in equity could signal underlying financial weaknesses, potentially affecting investor confidence and future capital raising.

Diaceutics Business Overview & Revenue Model

Company Description

Diaceutics (DXRX) is a data analytics and technology company specializing in precision medicine and diagnostics. The company operates primarily in the healthcare sector, providing solutions that enhance the development and commercialization of targeted therapies. Diaceutics offers a comprehensive platform that integrates diagnostic data, patient insights, and real-world evidence, enabling pharmaceutical companies to optimize their strategies in personalized medicine, improve patient outcomes, and streamline the diagnostic journey.

How the Company Makes Money

Diaceutics generates revenue through a combination of subscription fees, consulting services, and data analytics solutions. The company offers a subscription-based model for its DXRX platform, where pharmaceutical companies pay for access to advanced analytics and insights that help them navigate the complexities of precision medicine. Additionally, Diaceutics provides consulting services that assist clients in understanding market dynamics and developing strategies for effective product launches. Key revenue streams include partnerships with pharmaceutical companies, which often involve long-term contracts for data services and analytics tools. The company also benefits from collaborations with diagnostic laboratories and healthcare organizations, enhancing its ability to provide comprehensive solutions and expanding its customer base.

Diaceutics Financial Statement Overview

Summary

Diaceutics demonstrates strong revenue growth but faces challenges in profitability and cash flow management. The balance sheet is robust with high equity and low leverage, providing a cushion against financial instability.

Income Statement

Diaceutics has shown significant revenue growth from the previous year, with a revenue increase of 35.71% in 2024 compared to 2023. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins, which suggest high operational costs relative to revenue. Despite a positive EBITDA margin, the overall profitability is challenged by persistent losses.

Balance Sheet

The company's balance sheet is relatively strong with a high equity ratio of 82.00%, indicating a stable financial foundation and minimal reliance on debt, as shown by a low debt-to-equity ratio of 0.03. However, the declining trend in stockholders' equity over the years raises concerns about the sustainability of this stability.

Cash Flow

Diaceutics has experienced a decline in free cash flow, moving from a positive value in 2022 to negative in 2024, highlighting challenges in operational cash generation. The operating cash flow to net income ratio suggests issues in converting income to cash, which could impact liquidity. Despite these challenges, the company maintains a cautious approach to financing activities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	34.40M	32.16M	23.70M	19.50M	13.94M	12.70M
Gross Profit	29.63M	28.27M	19.71M	14.04M	10.57M	9.33M
EBITDA	2.69M	2.77M	2.36M	3.61M	2.35M	178.00K
Net Income	-1.52M	-1.70M	-1.75M	724.00K	561.00K	263.00K
Balance Sheet
Total Assets	44.42M	48.62M	46.34M	48.26M	45.01M	43.52M
Cash, Cash Equivalents and Short-Term Investments	10.38M	12.74M	16.67M	19.84M	19.68M	25.25M
Total Debt	1.13M	1.06M	1.21M	1.33M	1.56M	118.00K
Total Liabilities	7.18M	8.76M	5.56M	5.74M	4.36M	3.28M
Stockholders Equity	37.24M	39.86M	40.79M	42.51M	40.65M	40.24M
Cash Flow
Free Cash Flow	10.00K	-3.98M	-3.54M	278.00K	-5.03M	-6.04M
Operating Cash Flow	104.00K	651.00K	1.31M	5.15M	570.00K	253.00K
Investing Cash Flow	-5.76M	-4.03M	-4.21M	-4.87M	-5.60M	-6.29M
Financing Cash Flow	-242.00K	-64.00K	-239.00K	-132.00K	-270.00K	19.61M

Diaceutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 161.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:DXRX, the sentiment is Negative. The current price of 161.5 is above the 20-day moving average (MA) of 142.43, above the 50-day MA of 154.59, and above the 200-day MA of 137.18, indicating a bearish trend. The MACD of -7.04 indicates Positive momentum. The RSI at 17.30 is Positive, neither overbought nor oversold. The STOCH value of 11.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:DXRX.

Diaceutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKF	67 Neutral	£112.29M	19.11	8.71%	―	-1.43%	28.57%
VRCI	58 Neutral	£11.73M	-0.32	-122.54%	―	-57.03%	-15.71%
DXRX	57 Neutral	£108.29M	-71.11	-3.95%	―	31.83%	46.59%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCLP	46 Neutral	£103.78M	-7.58	―	―	―	-94.12%
AVCT	42 Neutral	£270.90M	―	―	―	―	―
AGL	40 Underperform	―	―	-87.18%	―	29.64%	28.51%

Diaceutics Corporate Events

Diaceutics PLC Expands Employee Share Incentive Plan

Diaceutics PLC has announced that trustees of its 2020 Employee Benefit Trust have purchased ordinary shares on behalf of certain key personnel as part of the company’s UK and Global Share Incentive Plan. These purchases, matched by the company with an equivalent number of shares, are part of an ongoing scheme to incentivize employees, reflecting Diaceutics’ commitment to aligning employee interests with company performance. The company has issued 5,221 shares to the UK Trust to settle these matched share awards, contributing to the total of 84,905,949 shares in issue, which shareholders can use to determine their interest in the company under regulatory guidelines.

Diaceutics PLC Enhances Employee Engagement with Share Incentive Plan

Diaceutics PLC has announced that its trustees have purchased ordinary shares on behalf of key personnel as part of the company’s Share Incentive Plan (SIP) for employees. This initiative, which involves matching employee share purchases with a 1:1 share award, aims to facilitate employee participation in the company’s growth and aligns with their strategic goals to enhance stakeholder engagement and transparency.

Diaceutics Enhances Employee Incentives with Share Purchases

Diaceutics PLC has announced the purchase of ordinary shares by trustees of the Global Diaceutics plc 2020 Employee Benefit Trust on behalf of certain PDMRs under the company’s UK and Global Share Incentive Plan. The company has matched these purchases with a share award, and issued 5,176 shares to the UK Trust to facilitate trading. This move is part of their ongoing commitment to incentivize employees and aligns with their strategy to enhance stakeholder value.

Diaceutics PLC Reports Strong H1 2025 Results, On Track for Profitability

Diaceutics PLC reported strong financial results for the first half of 2025, with a 22% revenue growth on a constant currency basis, reaching £14.6 million. The company is on track to achieve full-year profitability, supported by a solid order book and increased annual recurring revenue. Diaceutics has expanded its customer base and therapeutic brands, reinforcing its position as a primary commercialization partner for pharma and biotech companies. The company has made significant investments in AI and platform upgrades, which are expected to drive future growth and operational leverage. Despite global economic uncertainties, Diaceutics remains confident in meeting its profitability targets for 2025, highlighting its strategic focus on precision medicine and sustainable profitability.

Diaceutics to Announce Half-Year Results and Host Investor Webinar

Diaceutics PLC announced it will release its unaudited half-year results for the period ending 30 June 2025 on 23 September 2025. The company will also hold a webinar presentation for analysts and investors on the same day, indicating a proactive approach to engaging stakeholders and maintaining transparency in its operations.